Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage
Stefan M Gehrig, James G Ryall, Jonathan D Schertzer, Gordon S Lynch
EXPERIMENTAL PHYSIOLOGY | WILEY | Published : 2008
Contraction-mediated injury is a major contributing factor to the pathophysiology of muscular dystrophy and therefore therapies that can attenuate this type of injury have clinical relevance. Systemic administration of insulin-like growth factor-I (IGF-I) has been shown to improve muscle function in dystrophic mdx mice, an effect associated with a shift towards a more oxidative muscle phenotype and a reduced susceptibility to contraction-mediated damage. The actions of IGF-I in vivo are modulated by IGF binding proteins (IGFBPs), which generally act to inhibit IGF-I signalling. We tested the hypothesis that an analogue of IGF-I (LR IGF-I), which has significantly reduced binding affinity for..View full abstract
Awarded by Muscular Dystrophy Association (USA)
This work was supported by research grants from the Muscular Dystrophy Association (USA; nos 3595 and 4167).